



Vivimed

Date:13/11/2013

To

BSE Limited
Listing Department
P.J.Towers,Dalal Street,
Mumbai – 400001

National Stock Exchange of India Ltd
Listing Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra(E),Mumbai – 400051

NSE- Symbol: VIVIMEDLAB

BSE - Code : 532660

Dear Sir/Madam

Sub: Outcome of the Meeting of the Board of Directors of the Company – reg

The Board of Directors of the Company at its meeting held on November 13, 2013, inter alia, have resolved and taken note of/approved the following :

1. Pursuant to clause 41 of Listing Agreement entered into with the stock exchanges, considered and approved the submission of the Unaudited financial results for the Quarter & Half year ended September 30,2013 attached herewith;

An earnings related presentation including business highlights will be uploaded on the company's website www.vivimedlabs.com

You are requested to take note of the above.

Yours faithfully

For VIVIMED LABS LTD

SANTOSH VARALWAR
MANAGING DIRECTOR & CEO



VIVIMED LABS LIMITED
CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED SEPTEMBER 30th, 2013

Rs in Lakhs

Sl. No.	Particulars	Quarter Ended				Previous Year ended 31-03-2013 (FY13)
		30.09.2013	30.06.2013	30.09.2012	30.09.2013	
1	Income From Operations	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
	(a) Net Sales / Income from Operations (Net of Excise Duty)	30,663.98	34,075.44	26,608.92	64,739.42	53,860.58
	(b) Other Operating Income	64.29	316.03	973.71	380.32	1,154.56
	Total Income from Operations (Net)	30,728.27	34,391.47	27,582.63	65,119.74	55,015.14
	a. Cost of Raw Materials Consumed	14,611.85	15,039.05	12,497.70	29,650.89	26,467.15
	b. Purchase of Stock in Trade	-	-	-	-	-
	c. Changes in Inventories of Finished Inventories of Finished Goods, Work-in-Progress and Stock in Trade	1,228.40	2,717.58	523.15	3,945.97	(2,451.50)
	d. Employee Benefit Expenses	1,645.59	1,556.09	1,240.34	3,201.68	2,664.88
	e. Depreciation and Amortisation Expenses	1,737.75	1,465.42	1,406.78	3,202.67	2,819.79
	f. Other Expenditure	8,003.59	10,195.31	7,932.45	18,198.90	16,751.87
	Total Expenses	27,226.67	30,973.45	23,600.42	58,200.12	46,251.98
	Profit / (Loss) from Operations before Other Income, Finance Costs and exceptional items (1 - 2)	3,501.60	3,418.03	3,982.21	6,919.63	8,763.16
	4 Other Income	-	-	-	-	-
	5 Profit / (Loss) from Ordinary Activities before Finance Costs and exceptional items (3 - 4)	3,501.60	3,418.03	3,982.21	6,919.63	8,763.16
	6 Finance Costs	1,715.11	985.65	1,075.40	2,700.76	2,664.45
	7 Profit / (Loss) from Ordinary Activities after Finance Costs but before exceptional items (5 - 6)	1,786.49	2,432.37	2,906.81	4,218.86	6,098.71
	8 Exceptional Items	-	-	-	-	-
	9 Profit / Loss from ordinary activities before Tax (7 - 8)	1,786.49	2,432.37	2,906.81	4,218.86	6,098.71
	10 Tax Expenses	148.51	433.92	353.10	582.43	932.03
	11 Net Profit / Loss from ordinary activities after Tax (9 - 10)	1,637.98	1,998.46	2,553.71	3,636.44	5,166.67
	12 Extraordinary Items (net of tax expenses Rs.....lacs)	-	-	-	-	-
	13 Net Profit / Loss for period (11 - 12)	1,637.98	1,998.46	2,553.71	3,636.44	5,166.67
	14 Share of Profit / (Loss) of associates	-	-	-	-	-
	15 Minority Interest	-	-	-	-	-
	16 Net Profit / Loss after taxes, Minority Interest and share of Profit / (Loss) of Associates (13 - 14 - 15)	1,637.98	1,998.46	2,553.71	3,636.44	5,166.67
	17 Paid up Equity Share Capital (Face value of the Share shall be indicated)	1,620.38	1,606.09	1,393.39	1,620.38	1,393.39
	18 Reserve excluding Revaluation Reserves as per Balance Sheet of Previous Accounting Year	-	-	-	-	-
	19 Earnings per Share (before Extraordinary Items) (of Rs...../- each) (not annualised)	10.11	12.44	18.33	22.44	37.08
	(a) Basic	10.11	12.44	18.33	22.44	37.08
	(b) Diluted	10.11	12.44	15.90	22.44	32.17

1. The above Consolidated Unaudited Financial Results for the Quarter ended September 30, 2013 have been reviewed by Audit Committee and taken on record by Board of Directors at their meeting held on 13th November, 2013.

2. Consolidated Financial Statements have been prepared in accordance with Accounting Standard - 21 issued by ICAI. Consolidated Results are combined numbers of Vivimed Labs Limited and its direct wholly owned subsidiaries, viz.: (i) Creative Healthcare Private Limited, (ii) Vivimed Labs USA, Inc., (iii) Klar Schen Private Limited, (iv) Ozonite Nobel Labs Private Limited, (v) Vivimed Labs (Austria) pvt. Ltd., (vi) Vivimed Holdings Limited and its step down subsidiary viz: (a) Vivimed Labs Europe Limited (vii) Vivimed Labs Mauritius Limited and its step down subsidiaries (a) Vivimed Labs UK Limited, (b) Vivimed Labs Spain, S.L. with its subsidiaries (i) Union Quimica Farmaceutica S.A.U., Spain, (ii) Holiday International Limited, UK, and its further subsidiary Uquifo Mexico S.A. de C.V. &

3. The Company opted to publish only Consolidated Financial Results. Standalone results of the Company will be available on Company's website www.vivimedlabs.com and also on BSE & NSE websites.

4. As per Accounting Standard 17 on Segment Reporting (AS-17), results of the two segments "Specialty Chemicals" and "Pharma" are reported.

5. Corresponding numbers of previous period / year have been revised, regrouped, wherever necessary.

For VIVIMED LABS LIMITED

(SANTOSH VARMA)

MANAGING DIRECTOR & CEO



VIVIMED LABS LIMITED

SEGMENT-WISE CONSOLIDATED FINANCIAL RESULTS AND CAPITAL EMPLOYED UNDER CLAUSE - 41 OF THE LISTING AGREEMENT

Rs in Lakhs

Particulars	3 Months Ended			6 Months Ended		Year Ended
	30.09.2013 (Unaudited)	30.06.2013 (Unaudited)	30.09.2012 (Unaudited)	30.09.2013 (Unaudited)	30.09.2012 (Unaudited)	
1. Segment Revenue (net sales/income from each segment should be disclosed under this head)						
a. Speciality Chemicals Business	9,937.67	9,833.75	9,407.19	19,771.42	18,234.44	37,038.67
b. Pharma Business	20,726.31	24,241.69	17,201.73	44,968.00	35,626.14	73,840.89
Total	30,663.98	34,075.44	26,608.92	64,739.42	53,860.58	1,10,879.56
Less, Inter Segment Revenue						
Net sales / Income from Operations	30,663.98	34,075.44	26,608.92	64,739.42	53,860.58	1,10,879.56
2. Segment Results (Profit) (+) / Loss (-) before tax and interest from each segment						
a. Speciality Chemicals Business	2,113.11	1,499.23	1,896.46	3,612.34	3,866.25	6,826.37
b. Pharma Business	1,388.49	1,918.79	2,085.72	3,307.28	4,896.91	7,054.37
Total	3,501.60	3,418.02	3,982.18	6,919.62	8,763.16	13,880.74
Less: 1. Interest	1,715.11	985.65	1,075.40	2,700.76	2,664.45	4,093.18
2. Other Un-allocable Expenditure						
3. Un-allocable Income						
Total Profit Before Tax	1,786.49	2,432.37	2,906.78	4,218.86	6,098.71	9,787.56
3. Capital Employed						
a. Speciality Chemicals Business	80,666.88	79,125.29	81,276.11	80,666.88	81,276.11	77,724.60
b. Pharma Business	60,838.64	50,135.20	45,784.65	60,838.64	45,784.65	51,568.93
Total	1,41,505.52	1,29,260.49	1,27,060.76	1,41,505.52	1,27,060.76	1,29,293.52

For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)
MANAGING DIRECTOR & CEO



Place : Hyderabad
Date : 13.11.2013

VIVIMED LABS LIMITED
STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED SEPTEMBER 30th, 2013

Rs in Lakhs

Sl. No.	Particulars	Quarter Ended			Half Year Ended		Previous Year ended 31-03-2013 (FY13)
		30.09.2013	30.06.2013	30.09.2012	30.09.2013	30.09.2012	
1	Income From Operations	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
	(a) Net Sales / Income from Operations (Net of Excise Duty)	10,227.74	9,850.63	10,958.42	20,078.37	20,074.48	42,312.51
	(b) Other Operating Income	10.03	14.85	155.57	24.88	194.50	337.93
	Total Income from Operations (Net)	10,237.77	9,865.48	11,113.99	20,103.25	20,268.98	42,650.44
	a. Cost of Raw Materials Consumed	5,703.56	5,405.74	6,047.12	11,109.30	12,522.93	24,736.98
	b. Purchase of Stock in Trade	-	-	-	-	-	-
	c. Changes in Inventories of Finished Inventories of Finished Goods, Work-in Progress and Stock in Trade	39.71	403.39	644.46	443.10	(1,384.16)	(755.32)
	d. Employee Benefit Expenses	620.66	510.95	414.23	1,131.61	755.97	1,550.85
	e. Depreciation and Amortisation Expenses	489.47	406.17	380.30	895.64	752.73	1,720.68
	f. Other Expenditure	1,754.90	1,571.17	1,491.75	2,777.07	3,534.47	7,415.35
2	Total Expenses	8,108.31	8,243.42	8,977.86	16,351.22	16,181.94	34,668.54
3	Profit / (Loss) from Operations before Other Income, Finance Costs and exceptional items (1 - 2)	2,129.47	1,622.06	2,136.13	3,751.53	4,087.04	7,981.90
4	Other Income	-	-	-	-	-	-
5	Profit / (Loss) from Ordinary Activities before Finance Costs and exceptional items (3 - 4)	2,129.47	1,622.06	2,136.13	3,751.53	4,087.04	7,981.90
6	Finance Costs	1,264.57	583.53	680.81	1,848.10	1,575.82	2,843.78
7	Profit / (Loss) from Ordinary Activities after Finance Costs but before exceptional items (5 - 6)	864.90	1,038.53	1,455.32	1,903.43	2,511.22	5,138.11
8	Exceptional Items	-	-	-	-	-	-
9	Profit / Loss from ordinary activities before Tax (7 - 8)	864.90	1,038.53	1,455.32	1,903.43	2,511.22	5,138.11
10	Tax Expenses	172.98	207.71	537.95	380.69	749.12	1,464.55
11	Net Profit / Loss from ordinary activities after Tax (9 - 10)	691.92	830.82	917.37	1,522.74	1,762.10	3,673.56
12	Extraordinary Items (net of tax expenses Rs. (Loss)	-	-	-	-	-	-
13	Net Profit / Loss for period (11 - 12)	691.92	830.82	917.37	1,522.74	1,762.10	3,673.56
14	Share of Profit / (Loss) of associates	-	-	-	-	-	-
15	Minority Interest	-	-	-	-	-	-
16	Net Profit / Loss after taxes, Minority Interest and Share of Profit / (Loss) of Associates (13 - 14 - 15)	691.92	830.82	917.37	1,522.74	1,762.10	3,673.56
17	Paid up Equity Share Capital (face value of the Share shall be indicated)	1,620.38	1,606.09	1393.39	1,620.38	1,393.39	1,606.09
18	Reserve excluding Revaluation Reserves as per Balance Sheet of Previous Accounting Year	-	-	-	-	-	-
19	Earnings per Share (before Extraordinary Items) (of Rs. / each) (not annualised)	4.22	5.17	6.58	9.40	12.65	22.87
	(b) Diluted	4.27	5.17	5.71	9.40	10.97	22.87

1. The above Standalone Unaudited Financial Results for the Quarter ended 30th September, 2013 have been reviewed by Audit Committee and taken on record by Board of Directors at their meeting held on 13th November 2013.

2. The Company opted to publish only Consolidated Financial Results. Standalone results of the Company will be available on Company's website www.vivimedlabs.com and also on BSE & NSE websites.

3. As per Accounting Standard 17 on Segment Reporting (AS-17), results of the two Segments "Specialty Chemicals" and "Pharma" are reported.

4. Corresponding numbers of previous period / year have been revised, regrouped, wherever necessary.

For VIVIMED LABS LIMITED

(SANTOSH KAPILWAR)
 MANAGING DIRECTOR & CEO



Place : Hyderabad
 Date : 13.11.2013

VIVIMED LABS LIMITED
SEGMENT-WISE STANDALONE FINANCIAL RESULTS AND CAPITAL EMPLOYED UNDER CLAUSE - 41 OF THE LISTING AGREEMENT

Rs in Lakhs

Particulars	3 Months Ended			6 Months Ended			Year Ended 31.03.2013 (Audited)
	30.09.2013 (Unaudited)	30.06.2013 (Unaudited)	30.09.2012 (Unaudited)	30.09.2013 (Unaudited)	30.09.2012 (Unaudited)	31.03.2013 (Audited)	
1. Segment Revenue (net sales/income from each segment should be disclosed under this head)							
a. Speciality Chemicals Business	8,585.39	7,575.10	8,582.74	16,160.49	15,430.76	32,864.44	
b. Pharma Business	1,642.35	2,275.53	2,375.68	3,917.88	4,643.72	9,448.07	
Total	10,227.74	9,850.63	10,958.42	20,078.37	20,074.48	42,312.51	
Less, Inter Segment Revenue							
Net sales / Income from Operations	10,227.74	9,850.63	10,958.42	20,078.37	20,074.48	42,312.51	
2. Segment Results (Profit) (+) / Loss (-) before tax and interest from each segment							
a. Speciality Chemicals Business	1,921.46	1,177.90	1,799.35	3,099.36	3,323.96	6,410.83	
b. Pharma Business	208.01	444.17	336.78	652.18	763.08	1,571.07	
Total	2,129.47	1,622.07	2,136.13	3,751.54	4,087.04	7,981.90	
Less: 1. Interest	1,264.57	583.53	680.81	1,848.10	1,575.82	2,843.78	
2. Other Un-allocable Expenditure							
3. Un-allocable Income							
Total Profit Before Tax	864.90	1,038.54	1,455.32	1,903.44	2,511.22	5,138.11	
3. Capital Employed							
a. Speciality Chemicals Business	81,111.67	81,509.27	78,359.87	81,111.67	78,359.87	77,019.49	
b. Pharma Business	21,333.46	7,642.99	7,380.55	21,333.46	7,380.55	7,554.32	
Total	1,02,445.13	89,152.26	85,740.42	1,02,445.13	85,740.42	84,573.81	

For VIVIMED LABS LIMITED

(SANTOSH YABALWAR)
 MANAGING DIRECTOR & CEO



Place : Hyderabad
 Date : 13.11.2013

S.No	Particulars	STANDALONE		CONSOLIDATED	
		As at	As at	As at	As at
		30.09.2013 Unaudited	31.03.2013 Audited	30.09.2013 UnAudited	31.03.2013 Audited
(A)	EQUITY AND LIABILITIES				
1	Shareholders funds				
	(a) Share Capital				
	i) Equity Share Capital	1,620.38	1,606.09	1,620.38	1,606.09
	ii) Preference Share capital		-	6,394.56	6,394.56
	(b) Reserves and Surplus	31,759.30	32,801.31	44,490.06	42,676.58
	(c) Money Received against Share Warrants	237.21	237.21	237.21	237.21
	Sub Total Shareholders Funds	33,616.88	34,644.61	52,742.21	50,914.44
2	Non-current liabilities				
	(a) Long-term borrowings	23,721.11	18,394.47	37,274.70	29,692.04
	(b) Deferred tax liabilities (net)	2,666.72	2,666.72	2,038.85	1,719.87
	(c) Other long-term liabilities	16,084.48	6,119.98	16,199.29	13,409.60
	(d) Long-term provisions	209.65	197.23	403.16	146.67
	Sub-total - Non-current liabilities	42,681.96	27,378.40	55,916.00	44,968.18
3	Current liabilities				
	(a) Short-term borrowings	26,146.29	22,562.63	32,847.31	30,112.73
	(b) Trade payables	5,175.31	4,683.36	21,000.07	16,627.85
	(c) Other current liabilities	5,691.82	5,012.92	12,777.81	11,610.15
	(d) Short-term provisions	1,714.37	1,197.41	4,411.06	2,722.30
	Sub-total - Current liabilities	38,727.79	33,456.32	71,036.25	61,073.04
	TOTAL - EQUITY AND LIABILITIES	1,15,026.63	95,479.34	1,79,694.46	1,56,955.66
(B)	ASSETS				
1	Non-current assets				
	(a) Fixed assets				
	(i) Tangible Assets	39,057.09	39,039.35	67,543.29	63,336.96
	(ii) Intangible Assets	1,394.70	1,468.20	8,769.90	7,566.86
	(iii) Capital work in progress	891.73	921.29	2,990.44	2,691.75
	(b) Non Current Investment	21,754.55	9,554.55	24.35	24.35
	(c) Long Term Loans and advances	-	-	-	-
	(d) Other Non Current Assets	5.92	5.92	2,114.02	1,827.06
	Sub-total - Non-current assets	63,104.00	50,989.31	81,442.00	75,446.98
2	Current Assets				
	(a) Inventories	18,475.95	14,035.86	42,449.07	34,026.28
	(b) Trade receivables	17,759.67	16,005.97	34,851.08	30,822.50
	(c) Cash and cash equivalents	1,447.36	1,366.67	3,992.49	2,395.72
	(d) Short-term loans and advances	13,646.50	12,488.39	13,980.57	11,982.42
	(e) Other current assets	593.14	593.14	2,979.26	2,281.75
	Sub-total - Current assets	51,922.63	44,490.02	98,252.46	81,508.68
	TOTAL - ASSETS	1,15,026.63	95,479.33	1,79,694.46	1,56,955.66



(Handwritten signature)



P. MURALI & CO.,

CHARTERED ACCOUNTANTS
6-3-655/2/3, SOMAJIGUDA,
HYDERABAD - 500 082. INDIA

Tel. : (91-40) 2332 6666, 2331 2554
2339 3967, 2332 1470
Fax : (91-40) 2339 2474
E-mail : pmurali.co@gmail.com
info@pmurali.com
Website : www.pmurali.com

To
The Board of Directors
M/S. VIVIMED LABS LIMITED.
Plot No. 78-A, Kolhar Industrial Area,
Bidar- 585403,
Karnataka

Limited Review Report for the quarter ended 30th September, 2013

We have reviewed the accompanying statement of unaudited financial results of **M/S. VIVIMED LABS LIMITED**, for the quarter ended 30th September, 2013 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.


We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For P. Murali & Co.
Chartered Accountants



Place: Hyderabad
Date: 13th November, 2013


Partner
MUKUND VIJAYARAO JOSHI
Chartered Accountant
Membership No:024784